Results 1 to 10 of about 293,289 (203)

Polycythemia Vera Revealed by Acute Myocardial Infarction: A Case Report [PDF]

Reports
Background and Clinical Significance: Polycythemia vera is a myeloproliferative neoplasm associated with a high thrombotic risk. Although this association is well recognized, acute coronary syndrome as the initial manifestation of polycythemia vera is ...
Jéni Quintal, Raquel Flores, Tatiana Duarte, Ana Santo António, Filipe Seixo   +4 more
doaj   +2 more sources

Polycythemia Vera and Essential Thrombocythemia: A Nationwide Population-Based Study on Treatment Patterns, Vascular Complications and Survival. [PDF]

Eur J Haematol
ABSTRACT Background Polycythemia vera (PV) and essential thrombocythemia (ET) are associated with a well‐recognized increased risk of thrombotic events, bleeding, and all‐cause mortality, but the frequency of these outcomes during treatment has rarely been assessed in large cohorts.
Larsson AE, Renlund H, Andréasson B, Holmberg H, Liljeholm M, Själander A.   +5 more
europepmc   +2 more sources

Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera.

PLoS ONE, 2020
The myeloproliferative neoplasms, polycythemia vera, essential thrombocytosis and primary myelofibrosis are hematopoietic stem cell disorders and share driver mutations that either directly activate the thrombopoietin receptor, MPL, or activate it ...
Jerry L Spivak, Akil Merchant, Donna M Williams, Ophelia Rogers, Wanke Zhao, Amy Duffield, Linda S Resar, Alison R Moliterno, Zhizhuang J Zhao   +8 more
doaj   +2 more sources

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study

Haematologica, 2020
We report the final 2-year end-of-study results from the first clinical trial investigating combination treatment with ruxolitinib and low-dose pegylated interferon-α2 (PEG-IFNα2).
Anders Lindholm Sørensen, Stine Ulrik Mikkelsen, Trine Alma Knudsen, Mads Emil Bjørn, Christen Lykkegaard Andersen, Ole Weis Bjerrum, Nana Brochmann, Dustin Andersen Patel, Lise Mette Rahbek Gjerdrum, Daniel El Fassi, Torben A. Kruse, Thomas Stauffer Larsen, Hans Torben Mourits-Andersen, Claus Henrik Nielsen, Christina Ellervik, Niels Pallisgaard, Mads Thomassen, Lasse Kjær, Vibe Skov, Hans Carl Hasselbalch   +19 more
doaj   +2 more sources

Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review

Haematologica, 2019
Although it is well known that myeloproliferative neoplasms occur in younger patients, few large cohorts of such patients have been reported. Thus, our knowledge about circumstances of diagnosis, outcome and treatment is limited, especially for children ...
Jean-Christophe Ianotto, Natalia Curto-Garcia, Marie Lauermanova, Deepti Radia, Jean-Jacques Kiladjian, Claire N. Harrison   +5 more
doaj   +2 more sources

Diagnosis and Treatment of Polycythemia Vera: A Review. [PDF]

JAMA
Importance Polycythemia vera (PV), a myeloproliferative neoplasm characterized by an increased red blood cell mass and increased risk of thrombosis, affects approximately 65 000 people in the US, with an annual incidence of 0.5 to 4.0 cases per 100 000 ...
Tremblay D, Kremyanskaya M, Mascarenhas J, Hoffman R.   +3 more
europepmc   +2 more sources

Schizophrenia and Polycythemia Vera: A Case Report [PDF]

European Psychiatry
Introduction Schizophrenia is a severe mental disorder marked by abnormal interpretations of reality, often resulting in hallucinations, delusions, and disordered thinking that significantly impairs daily functioning and can be disabling.
N. El Moussaoui, S. Bahetta, I. Belabbes, F. Laboudi, A. Ouanass   +4 more
doaj   +2 more sources

Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management

American journal of hematology/oncology, 2023
Polycythemia vera (PV) is a JAK2‐mutated myeloproliferative neoplasm characterized by clonal erythrocytosis; other features include leukocytosis, thrombocytosis, splenomegaly, pruritus, constitutional symptoms, microcirculatory disturbances, and ...
A. Tefferi, T. Barbui
semanticscholar   +1 more source

Polycythemia vera is a medical condition characterized by raised hematocrit. Owing to increased viscosity, the blood flow in the vessels become sluggish leading to the clinical features of polycythemia such as headache, blurring of vision, red skin, dizzi

Journal of Bahria University Medical and Dental College, 2021
Polycythemia vera is a medical condition characterized by raised hematocrit. Owing to increased viscosity, the blood flow in the vessels become sluggish leading to the clinical features of polycythemia such as headache, blurring of vision, red skin ...
Nabeela Iqbal, Syed Khalid Shah, Shamima Haneef   +2 more
doaj   +1 more source

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

Journal of Clinical Oncology, 2023
PURPOSE Polycythemia vera (PV) is characterized by JAK/STAT activation, thrombotic/hemorrhagic events, systemic symptoms, and disease transformation. In high-risk PV, ruxolitinib controls blood counts and improves symptoms.
C. Harrison, J. Nangalia, R. Boucher, Aimee E Jackson, C. Yap, J. O'Sullivan, Sonia Fox, Isaak Ailts, A. Dueck, H. Geyer, Ruben A. Mesa, W. Dunn, Eugene Nadezhdin, N. Curto-Garcia, A. Green, B. Wilkins, J. Coppell, J. Laurie, M. Garg, J. Ewing, S. Knapper, Josephine Crowe, Frederick Chen, I. Koutsavlis, A. Godfrey, S. Arami, M. Drummond, J. Byrne, F. Clark, Carolyn Mead-Harvey, E. J. Baxter, M. McMullin, A. Mead   +32 more
semanticscholar   +1 more source